New York, USA | November 19, 2026
Researchers at NYU Langone Health have developed a genetically engineered mouse model that reproduces key characteristics of X-linked dystonia-parkinsonism (XDP), a rare inherited neurodegenerative disorder, using advanced genome-writing technology. The research, published in the scientific journal Cell, demonstrates how inserting human genetic material associated with a disease into the mouse genome can accelerate disease development and support the investigation of potential treatments. By introducing approximately 78,000 human DNA base pairs (78 kilobases) containing disease-associated genetic elements into the mouse TAF1 gene, researchers successfully reproduced important molecular and neurological features of XDP. Remarkably, the engineered mice developed disease symptoms in approximately 1.5 months compared with up to 30 years in humans, creating a significantly faster experimental model for studying disease mechanisms and evaluating future therapeutic approaches.
Genome-Writing Technology Reproduces Human Genetic Disease in Mice
The research team used an advanced genetic engineering approach known as genome writing to introduce human disease-associated DNA sequences into the mouse genome. The study focused on X-linked dystonia-parkinsonism, a progressive neurological condition characterized by involuntary movements, muscle abnormalities and worsening motor dysfunction. The disease is associated with the insertion of SINE-VNTR-Alu (SVA) transposable elements into the human TAF1 gene. These genetic elements are unique to humans and are not naturally present in mice, which has historically made it difficult to reproduce the disease accurately in conventional animal models. To overcome this limitation, researchers modified a portion of the mouse Taf1 gene by incorporating approximately 78 kilobases of human genetic material, including the disease-associated SVA sequences. The resulting humanized mouse model reproduced several important characteristics of XDP, including reduced TAF1 protein expression, cellular damage, brain abnormalities and movement disorders. The findings confirmed that the inserted SVA elements interfere with normal gene transcription, reducing the production of TAF1 protein required for essential cellular functions. This approach provides researchers with an experimental system that more closely represents the genetic mechanisms responsible for the human condition.
Accelerated Disease Development Creates Opportunities for Treatment Research
One of the most important findings was the speed at which the genetically engineered mice developed disease characteristics. While XDP can take approximately three decades to become clinically apparent in affected individuals, the humanized mice developed recognizable disease features in approximately 1.5 months, representing an acceleration of up to 300 times compared with human disease progression. This shortened experimental timeline could help scientists investigate disease mechanisms, study genetic changes and evaluate potential therapeutic strategies more efficiently. Researchers also investigated whether increasing TAF1 expression could counteract the molecular effects of the disease-associated genetic insertion. Using CRISPR-based dCas9 technology, the team successfully increased TAF1 expression in stem cells and demonstrated that the reduction caused by the SVA insertion could be reversed at the molecular level. Although this represents an early experimental finding rather than an established treatment, it provides a scientific rationale for exploring approaches that restore normal TAF1 activity. According to senior study author Jef D. Boeke, the findings establish a foundation for developing future therapeutic strategies for individuals affected by XDP. The researchers also believe that similar genome-writing approaches could potentially be adapted to create experimental models for other rare genetic disorders that are difficult to reproduce in animals.
Companion Study Identifies Myelin-Producing Cells in XDP
A companion study published in the same edition of Cell identified another important aspect of XDP biology. Researchers found that oligodendrocytes, specialized brain cells responsible for producing myelin, play a significant role in the disease. Myelin forms a protective insulating layer around nerve fibres and supports efficient communication between neurons. Using the humanized XDP mouse model, the research team identified substantial reductions in oligodendrocyte populations and widespread disruption of myelin in affected brain regions. Importantly, similar myelin abnormalities were also identified in previously collected human XDP brain tissue. This discovery challenges earlier assumptions that neuronal loss alone explains the neurological damage associated with the condition and highlights the importance of supporting brain cells in disease progression. Together, the two studies provide new insights into TAF1 gene regulation, oligodendrocyte dysfunction and myelin loss in XDP. The research could support future investigations into genetic therapies and other approaches targeting the underlying biological mechanisms of rare neurodegenerative diseases. However, additional preclinical research and clinical studies will be required before any potential therapeutic strategy can be established as safe and effective in patients.
About the Research: The studies were led by investigators at NYU Langone Health, with contributions from researchers at Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, the University of Freiburg and other collaborating institutions. The research was supported by the Collaborative Center for X-Linked Dystonia-Parkinsonism and several National Institutes of Health grants, alongside additional institutional and philanthropic funding.
Source: NYU Langone Health press release


